Sartorius Stedim Biotech: Berenberg initiates as a buyer
(CercleFinance.com) - Berenberg said on Friday that it is initiating coverage of Sartorius Stedim Biotech with a buy rating, believing it a good way to play the bioprocess theme.
The broker - which has a target price of 342 euros - stresses that biological drugs (antibodies, vaccines, gene therapies) today represent nearly 30% of the world pharmaceutical industry and that their weight should continue to grow over the next decade.
In order to sustain this rapid growth rate, the use of single-use technologies is essential to feed a market, which is now worth several billion dollars and is growing at an annual rate of 11% to 12%, the broker explains.
It says that the group has a long experience of winning market share and expects this momentum to continue.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The broker - which has a target price of 342 euros - stresses that biological drugs (antibodies, vaccines, gene therapies) today represent nearly 30% of the world pharmaceutical industry and that their weight should continue to grow over the next decade.
In order to sustain this rapid growth rate, the use of single-use technologies is essential to feed a market, which is now worth several billion dollars and is growing at an annual rate of 11% to 12%, the broker explains.
It says that the group has a long experience of winning market share and expects this momentum to continue.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.